Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.

The company posted third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.

Organon lowered its fiscal sales guidance from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion, below the consensus of $6.289 billion.

“I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon’s Interim Chief Executive Officer. “We are harnessing the company’s many strengths, including a diverse portfolio that we expect will generate ...